

News Releases

All Years



Search

GO

[Advanced Search](#)

Aug 6, 2019

Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe

- Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the Company's first sales of Ondexxya® (andexanet alfa) in Europe. These sales mark the initiation of commercial access in Europe to...

Aug 5, 2019

U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa

- Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology...

Jul 17, 2019

Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and...

Jul 8, 2019

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors

- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new invitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and...

Jun 19, 2019

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

Show 5



per

[<](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ... [49](#) [>](#)

page



<https://investors.portola.com/news-releases?o=10>